Welcome to our dedicated page for Silexion Therapeutics SEC filings (Ticker: SLXN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Silexion Therapeutics Corp (SLXN) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as a clinical-stage biotechnology issuer listed on the Nasdaq Capital Market. Silexion files current reports on Form 8-K, registration statements, and other documents that describe its RNA interference (RNAi) programs for KRAS-driven cancers, financing activities, and corporate developments.
Through its Form 8-K filings, Silexion furnishes press releases on key events such as positive preclinical data for its lead siRNA candidate SIL204, completion of toxicology studies, written Scientific Advice from Germany’s Federal Institute for Drugs and Medical Devices (BfArM) on its planned Phase 2/3 trial in locally advanced pancreatic cancer, and submission of a clinical trial application in Israel. Other 8-Ks detail capital-raising transactions, including public offerings and an at-the-market offering agreement, as well as Nasdaq correspondence confirming restoration of compliance with minimum bid price and shareholders’ equity listing requirements.
Investors can also review registration statements such as the Form S-1, which outlines Silexion’s status as a Cayman Islands–incorporated emerging growth company, its ordinary share and warrant structures, and risk disclosures associated with its clinical-stage oncology business. Over time, periodic reports on Forms 10-K and 10-Q (when available) provide additional information on research and development expenses, general and administrative costs, and accumulated deficit.
On Stock Titan, these filings are supplemented with AI-powered summaries that highlight the main points of lengthy documents, helping users quickly understand new financings, regulatory milestones, and material agreements. Real-time updates from EDGAR, along with structured access to Forms 8-K, registration statements, and other filings, allow users to track how Silexion describes its KRAS-focused RNAi pipeline, clinical plans for SIL204, and capital resources in its official SEC disclosures.
The reporting persons—Lind Global Fund III LP, Lind Global Partners III LLC and Jeff Easton—filed a Schedule 13G reporting beneficial ownership of 224,050 ordinary shares of Silexion Therapeutics Corp (CUSIP G1281K122), representing 9.9% of the class. The disclosed position consists of 106,250 ordinary shares and warrants (106,250 Series A-1 and 106,250 Series A-2) subject to conversion limits that cap aggregate beneficial ownership at 224,050 shares to prevent ownership above 9.99%. Lind Global Partners III LLC is the general partner of the fund and Jeff Easton is the managing member; each may be deemed to have sole voting and dispositive power over the reported shares. The filers certify the holdings were not acquired to change or influence control of the issuer.
Silexion Therapeutics Corp disclosed that three reporting persons—Intracoastal Capital, LLC, Mitchell P. Kopin and Daniel B. Asher—may each be deemed to beneficially own 244,771 ordinary shares, representing 9.99% of the class as of close of business on September 17, 2025. The filing explains these shares arise primarily from warrants issued under a Securities Purchase Agreement and notes multiple warrants include blocker provisions that limit exercise to prevent ownership above 9.99% (and 4.99% for one warrant). Voting and dispositive power over the 244,771 shares is reported as shared rather than sole.
Orca Capital AG reported beneficial ownership of 109,432 ordinary shares of Silexion Therapeutics Corp, representing 4.9% of the outstanding class based on 2,123,892 shares outstanding after the issuer's registered offering. The filing clarifies that the reporting person also holds warrants for 153,068 ordinary shares but cannot exercise them to the extent doing so would increase beneficial ownership above 4.99% (the "4.99% Blocker"). Orca states the securities were not acquired to change or influence control of the issuer and reports sole voting and dispositive power over the reported shares.
Orca Capital AG disclosed ownership of 131,250 ordinary shares of Silexion Therapeutics Corp (CUSIP G1281K130), representing 6.2% of the outstanding class based on 2,123,892 shares after the issuer's registered offering. Orca reports sole voting and dispositive power over these shares. The filing notes Orca holds warrants for 262,500 additional shares but cannot exercise them to the extent doing so would increase its stake above a 4.99% blocker under the warrant terms. The statement affirms the position was not acquired to change or influence control of the issuer.
Lincoln Alternative Strategies LLC reported beneficial ownership of 131,250 ordinary shares of Silexion Therapeutics Corp., representing 6.18% of the outstanding common stock based on 2,123,892 shares outstanding as of September 12, 2025. The filing on Schedule 13G states the shares are held with sole voting and dispositive power and that they were not acquired to change or influence control of the issuer. The report lists the filers Delaware organization, principal address in Miami Beach, FL, and is signed by Stephen Temes as Managing Member on September 15, 2025.
Silexion Therapeutics Corp filed a current report describing a new press release about its oncology candidate SIL204. On September 11, 2025, the company reported positive preclinical data showing SIL204’s reach and activity in major pancreatic cancer metastatic sites after systemic administration. The press release is included as Exhibit 99.1 and incorporated by reference for additional scientific details. The disclosure is furnished under Regulation FD, meaning it is intended to provide broad, non-selective access to this research update without being treated as filed financial information.
Silexion Therapeutics Corp filed an S-1 registration for an offering of ordinary shares, pre-funded warrants and ordinary warrants under Nasdaq tickers SLXN and SLXNW. The company is a development-stage RNAi therapeutics firm focused on KRAS-silencing candidates, including first-generation siG12D-LODER (Phase 1/2 data showing a numerical OS advantage in KRAS G12D/V patients) and second-generation SIL204 (preclinical stability, PK and in vivo efficacy data).
Financially, Silexion reported net losses of $16.5 million for 2024 (vs. $5.1 million in 2023) and had $3.5 million in cash as of June 30, 2025. Management states there is substantial doubt about the companys ability to continue as a going concern without additional financing. The S-1 discloses potential dilution from existing warrants, a $3.433 million promissory note convertible into shares, and an equity line (White Lion) that could issue up to $11.9 million of shares.
Silexion Therapeutics Corp filed a current report to share news from a recent press release. The company announced that it has selected a contract research organization to support its upcoming Phase 2/3 clinical trials for its candidate SIL 204, marking a step toward more advanced clinical development.
The press release, dated September 4, 2025, is included as Exhibit 99.1 and is furnished under Item 7.01, meaning it is provided for informational purposes and is not deemed filed under the Exchange Act or incorporated by reference into Securities Act filings.
Silexion Therapeutics Corp furnished an updated corporate presentation that it plans to present on September 10, 2025 at the H.C. Wainwright Global Investment Conference in New York. The presentation was posted on the company’s website on September 2, 2025 and attached as Exhibit 99.1.
The company clarifies that this information is provided under a disclosure item that treats the material as “furnished” rather than “filed”, meaning it is not subject to certain liability provisions and will only be incorporated into other securities documents if specifically referenced.
Silexion Therapeutics Corp (SLXN) filed an S-1 registering resale of up to 314,859 ordinary shares issuable upon exercise of warrants and discloses recent financings, operational results and liquidity constraints. For the six months ended June 30, 2025 the company reported a net loss of $4.238 million and cash and cash equivalents of $3.466 million. For the year ended December 31, 2024 net loss was $16.519 million, driven by higher R&D, G&A and financings costs. The company completed a public offering in January 2025 that generated approximately $5.0 million gross and subsequent warrant inducement transactions produced additional proceeds. Management notes substantial doubt about the company’s ability to continue as a going concern and disclosed Nasdaq listing compliance actions and two reverse share splits in 2024 and 2025.